Form 4: CRISPR Therapeutics Director Sandesh Mahatme Acquires 13,000 Stock Options

CRISPR Therapeutics AG Director Sandesh Mahatme has acquired 13,000 stock options with an exercise price of $38.57, vesting over 12 months.

Summary

• Sandesh Mahatme, a Director of CRISPR Therapeutics AG (CRSP), was granted 13,000 stock options.
• The options have an exercise price of $38.57 per common share.
• The grant date for these options was June 5, 2025.
• The options will vest 100% in 12 equal monthly installments, beginning on June 30, 2025.
• The final installment will vest on the earlier of the one-year anniversary of the grant date or the date of the 2026 Annual General Meeting of Shareholders.
• The stock options are exercisable at $38.57 and expire on June 5, 2035.
• Following this transaction, Sandesh Mahatme beneficially owns 13,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The document reports a routine grant of stock options to a director, which is a standard compensation practice. It aligns the director's interests with the company's long-term performance, which is generally viewed positively, but it does not contain new operational or financial performance data.

Positives

• The grant of 13,000 stock options to Director Sandesh Mahatme aligns his interests with long-term shareholder value creation.
• The structured 12-month vesting schedule encourages continued commitment and performance from the director.

Future Outlook

The vesting schedule for the stock options extends over the next 12 months, indicating a continued alignment of the director's incentives with the company's performance through at least mid-2026.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to incentivize long-term performance and align management interests with shareholder value.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across publicly traded companies, including those in the biotechnology sector like CRISPR Therapeutics.
• The vesting schedule of 12 equal monthly installments is a common approach to retain talent and ensure continued commitment, comparable to practices at companies such as Editas Medicine (EDIT) or Intellia Therapeutics (NTLA) which also utilize equity-based compensation for their leadership.

Related Party Transactions

• The grant of stock options to Director Sandesh Mahatme represents a compensation transaction between the company and a related party (an insider).

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns management's long-term interests with shareholder value creation, potentially leading to improved performance.
• Director (Sandesh Mahatme): Receives equity-based compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• The stock options will continue to vest in 12 equal monthly installments, with the final vesting occurring by June 5, 2026, or the 2026 Annual General Meeting of Shareholders, whichever is earlier.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Biotechnology, Gene Editing